+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
N

Actively Recruiting

Healthy Volunteer

Researchers are conducting a nationwide study in South Africa to develop the first nationally representative blood pressure and anthropometric reference values for children aged 5 to under 18 years. This study addresses the lack of appropriate African ancestry data, which currently results in reliance on European and US standards that may not suit the South African paediatric population. The goal is to improve understanding of blood pressure and hypertension in children and to establish clinical guidelines tailored to this population. The study involves measuring blood pressure and body measurements in a randomized sample of approximately 22,464 school-aged children from all provinces and various urban, peri-urban, and rural settings. Data collection will take place over five years, capturing a diverse group representative of South Africas ethnic and socioeconomic backgrounds. These measurements will be used to create nomograms and inform national guidelines for hypertension management in children. Participants will have their blood pressure and anthropometric data collected during the study period. Researchers will analyze these data to determine normal reference values and develop clinical practice guidelines for managing childhood hypertension. The information gathered will also support community engagement and awareness initiatives. The studys findings aim to guide healthcare providers and inform national health policies for better paediatric hypertension care in South Africa.

Age: 5Years - 18YearsAll Genders
11 locations